FDA Adverse Event and
Products Experience Reports; Electronic Submissions
No
material or nonsubstantive change to a currently approved
collection
No
Regular
09/14/2021
Requested
Previously Approved
06/30/2022
06/30/2022
3,013,420
3,013,420
1,809,396
1,809,396
141,386,203
141,386,203
This ICR collects both mandatory and
voluntary information regarding adverse events associated with
FDA-regulated products that are submitted electronically using
agency data-collection applications. Because the agency continues
to move from a paper/manual submissions process for reporting
adverse events to an electronic systems process, the scope of the
ICR is limited to those product areas for which an electronic
portal has been developed. Respondents include both manufacturers
and distributors of FDA products, as well as individual consumers.
The information collected enables FDA to identify potential public
health threats and implement mitigation strategies as
appropriate.
Our estimated burden for the
information collection reflects an overall increase of 688,547
hours and a corresponding increase of 1,145,763 responses. The
majority of these adjustments is attributed to the shift in
mandatory reports associated with medical devices (mandatory
reports via the ESG), which had previously been counted under OMB
Control 0910-0291.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.